Этиотропное и патогенетическое лечение, профилактика


Оглавление

ЛИТЕРАТУРА

ЛИТЕРАТУРА

    • 1. Аляев Ю. Г., Кузьмичева Г. М., Руденко В. И., Рапопорт Л. М. Клиническое значение комплексного исследования мочевых камней. Материалы Пленума правления Российского общества урологов, Москва, 2003, стр. 58-59.
    • 2. Аляев Ю. Г., Руденко В. И., Рапопорт Л. М., Васильев П. В. Показания к цитратной терапии с целью подготовки к ДЛТ. Материалы Пленума правления Российского общества урологов, Москва, 2003, стр. 59-60.
    • 3. Амосов А. В. Растительный препарат Канефрон в урологической практике. Врач, 2000, №6, стр. 38-39.
    • 4. Антибактериальная химиотерапия. Материалы цикла усовершенствования врачей. Под редакцией проф. В. П. Яковлева с соавторами, Москва.- 2002, 263 с.
    • 5. Баранник С.В. История открытия нанобактерии//Науки о человеке - Сб. статей по материалам третьего конгресса молодых учёных и специалистов. - Томск, СГМУ. - 2002
    • 6. Баранник С.В., Науменко Н.А. Перспективы изучения нанобактерии в медицине//Сб. статей по результатам всероссийской 60-ой юбилейной научной студенческой научной конференции имени Н.И. Пирогова (23 - 25 апреля 2001г.) - Томск, 2002
    • 7. Белоусов Ю.Б., Моисеев В.С., Лепахин В.К. Клиническая фармакология и фармакотерапия: руководство для врачей. - М.:Юниверсум, 1993. - 398 с.
    • 8. Бертрам Г.Катцунг Базисная и клиническая фармакология: в 2-х томах./ Пер. с англ. - М.- СПб.: Бином - Невский Диалект, 1998, Т1 - 607с., Т2 - 670 с.
    • 9. Большая Российская энциклопедия лекарственных средств. Том 1-2. Ремедиум, Москва, 2001, 821 с.
    • 10. Гудер В.Г., С. Нарайанан, Г.Виссер, Б.Цавта // Пробы: от пациента до лаборатории. - GIT VERLAG, Germany, 2001.
    • 11. Дзеранов Н. К., Бешлиев Д. А. Лечение мочекаменной болезни - комплексная медицинская проблема./ Сonsilium-medicum: приложение - Урология. 2003, стр.18-22.
    • 12. Калинина С. Н., Тиктинский О. Л. , Александров В. П., Михайличенко В. В., Алетин Р. Р. Клиническая эффективность препарата Канефрон в лечение больных мочекаменной болезнью после оперативных вмешательств. Тезисы докладов VI Российского Национального Конгресса "Человек и лекарство", 19-23 апреля 1999г., Москва, с. 298.
    • 13. Камышников В.С. // Справочник по клинико-биохимической лабораторной диагностике. - Минск, 2002.
    • 14. Константинова О.В. Метаболические различия нерецидивного и рецидивного уролитиаза // Урология .-1999.-N 5.- С8-9.
    • 15. Литвицкий П. Ф. Патофизиология: Учебник: в 2-х томах.- М.:ГЭОТАР-МЕД, 2002. - 365с.
    • 16. Международная статистическая классификация болезней и проблем связанных со здоровьем. Десятый пересмотр (МКБ-10): Краткий вариант.-Мн.:ООО"Acap", 2001.-400с.
    • 17. Меньшиков В.В. // Клиническая лабораторная аналитика. - в 3-х томах. - М.: Медицина, 2000.
    • 18. Наследственные болезни обмена веществ. Справочное пособие для врачей. / Под ред. К. Д. Краснопольской. - М., РОО "Центр социальной адаптации и реабилитации детей "Фохат", 2005г. - 364 с.
    • 19. Пытель Ю. А., Золотарев И. И. Уратный нефролитиаз. М.:1995; 176 с.
    • 20. Руководство по нефрологии: Пер. с англ./ Под ред. Дж. А. Витворт, Дж. Р. Лоуренса., М.: Медицина, 2000, стр. 290-301.
    • 21. Руководство по урологии в 3-х томах./ Под ред. Н. А. Лопаткина. М.:Медицина, 1998.
    • 22. Секреты эндокринологии./ Пер. с англ. под. Ю. А. Князева, 2-е испр. и допол. Москва: Изд-во ЗАО "Бином", 2001, 464 с.
    • 23. Сэнфорд Д., Гилберт Д., Гербердинг Д., Сэнде М. Антибактериальная терапия. /Пер. с англ.- М.:Практика, 1996, 224 с.
    • 24. Тиктинский О.Л., Александров В.П. // Мочекаменная болезнь. - Санкт-Петербург, 2000, 384 с.
    • 25. Шабалин В.Н., Шатохина С.Н. Морфология биологических жидкостей человека.- М.: Хризостом, 2001.- 304с.
    • 26. Юрьева Э.А., Матковская Т.А., Елагина И.А., Столяров Ю.Ю. Бисфосфонаты в фармакотерапии костных заболеваний. Экспериментальная и клиническая фармакоология., 2000, том 63, С.74-79.
    • 27. Adams J.S., Song C.F., Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydro-chlorthiazide. Ann Inter Med 1999; 130: 658-660.
    • 28. Agreste A.S., Schor N., Heilberg I.P. The effect of hardness of drinking water upon calculi growth in rats. In: Borghi L., Meschi Т., Briganti A., Schianchi Т., Novarini A. eds. Kidney Stones (Proceedings of the 8th European Symposium on Urolithiasis). Editoriale Bios, Parma, Italy; 1999: 487.
    • 29. Agreste A.S., Schor N., Heilberg l.P. Mineral composition of natural (NW) and sparkling water (SW) and calculi growth in rats. In: Borghi L., Meschi Т., Briganti A., Schianchi Т., Novarini A. eds, Kidney Stones (Proceedings of the 8th European Symposium on Urolithiasis). Editoriale Bios, Parma, Italy; 1999: 489.
    • 30. Akos Pap M.D. The management of smooth muscle spasm. Budapest, 1998, 266 р.
    • 31. Allison M.J., Dawson K.A., Mayberry W.R., Foss J.G. Oxalobacter formigenes gen. nov. sp nov: oxalat degrading bacteria that inhabit the gastrointestinal tract. Arch Microbiol 1985;141:р.1-7.
    • 32. Amsden G.W., Schentag J.J. Tables of antimicrobial agent pharmacology. In: Mandell G.L., Bennet J.E., Dolin R., еds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone; 2000. p.566-89.
    • 33. Bataille P., Achard J.M., Foumier A. et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: р.1193-1205.
    • 34. Bataille P., Charransol G., Gregoire I. et al. Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones. J Urol 1983; 130: p.218-223.
    • 35. Barcelo P., Wuhl O., Servitge E., Rousaud A., Pak С.Y.С. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993; 150: p.1761-1764.
    • 36. Bjorklund M, Ciftcioglu N, Kajander EO, () Extraordinary survival of nanobacteria under extreme condition. Proc SPIE Int Soc Opt Eng 1998; 3441:p.123.
    • 37. Body J.J. Bisphosphonates as chemotherapeutic agents. Current opinion in oncologic, endocrine and metabolic investigational. // Drugs. 2000, Vol.2.p.155-181.
    • 38. Borghi L., Meschi Т., Amato F., Briganti A., Novarini A., Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155: p.839-843.
    • 39. Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991; 39: p.1283-1298.
    • 40. Breslau N.A., Brinkley L., Hill K.D., Pak С.Y.С. Relationship of animal protein-rich diet to kidney stone formation. J Clin Endocrinol Metab 1988; 66: p.140-146.
    • 41. Breslau N.A., McGuire J.L., Zerwekh J.E., Pak C.Y.C. The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism. J din Endocrinol Metab 1982; 55: p.369-373.
    • 42. Breslau N.A., Padalino P., Kok D.J., Kirn Y.G., Pak C.Y.C. Physicochemical effects of a new slow-release potassium phosphate preparation (Urophos-K) in absorptive hypercalciuria. J Bone Miner Res 1995; 10: p.95.
    • 43. Brinkley L.J., Gregory J., Pak C.Y.C. A further study of oxalate bioavailability in foods. J Urol 1990: 144: p.94-96.
    • 44. Burton S.K. Nanobacteria growth characteristics and biofilm formation. Proceedings American Society of Microbiology 101st General Meeting, May 20-24, 2001, Orlando. Abstract I-98, p 437.
    • 45. Bushinsky D.A., Bashir M.A., Riordon D.R., Nakagawa Y., Сое F.L., Grynpas M.D. Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int 1999; 55: p.602-612.
    • 46. Bushinsky D.A., Kirn M., Sessler N.E., Nakagawa Y., Сое F.L. Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats. Kidney Int 1994; 45: p.58-65.
    • 47. Carr RJ (1954) A new theory of the formation of renal calculi. Brit J Urol 26:p.105.
    • 48. Caudarella R., Rizzoli E., Buffa A., Bottura A., Stefoni S. Comparative study of the influence of 3 types of mineral water in patients with idiopathic calcium lithiasis. J Urol 1998; 159: p.658-663.
    • 49. Chan J. C.M. Renal tubular acidosis. - J. Pediatr., 1983, 102: p.327.
    • 50. Ciftcioglu N, Bjorklund M, Kajander E.O. Stone formation and calcification by nanobacteria in human body. Proc SPIE Int Soc Opt Eng 1998:3441:p.105.
    • 51. Ciftcioglu N, Kajander E.O. Growth factor for nanobacteria Proc SPIE Int Soc Opt Eng 2000;3755:p.113.
    • 52. Ciftcioglu N, Kajander E.O. Interaction of nanobacteria with cultured mammalian cells. Pathophysiology 1998:4:29.
    • 53. Ciftcioglu N, Kajander E.O., Miller-Hjelle M.A., Hjelle J.T. Nanobacteria: controversial pathogenes in nephrolithiasis and policystic kidney disease. Curr Opin Nephrol Hypertens 2001:10:445.
    • 54. Ciftcioglu N., Miller-Hjelle M.A., Hjelle J.T., Kajander E.O. Ingibition of nanobacteria by a modified microdilution method. Antimicrob Agents Chemoter 2002:46:2077.
    • 55. Ciftcioglu N., Pelttari A., Kajander E.O., Extraordinary growth phases of nanobacteria isolated fron mammalian blood. Proc SPIE Int Soc Opt Eng 1997:3111:429
    • 56. Cirillo M., Laurenzi M., Panarelli W., Stamler J. Urinary sodium to potassium ratio and urinary stone disease. Kidney Int 1994; 46: 1133-1139.
    • 57. Cisar J.O., Xu D-Q., Thompson J., Swaim W., Hu L, Kopepcko D.J., An alternative interpretation of nanobacteria-induced biomineralisation. Proc Natl Acad Sci USA 2000:97:11511.
    • 58. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nefron 1976;16:p.31-41.
    • 59. Curhan G.C., Willet W.C., Rimm E.B., Stampfer M.J. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: p.833-838.
    • 60. Curhan G.C., Willett W.C., Speizer F.E., Spiegelman D., Stampfer M.J. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Inter Med 1997; 126: p.497-504.
    • 61. Curhan G.C., Willett W.C., Speizer F.E., Stampfer M.J. Beverage use and risk of kidney stones in women. Ann Inter Med 1998; 128:p.534-540.
    • 62. Curhan G.C., Willett W.C., Speizer F.E., Stampfer M.J. Intake of vitamins B6 and С and the risk of kidney stones in women. J Am Soc Nephrol 1999; 10: p.840-845.
    • 63. Ettinger B. Hyperuricosuria and calcium oxalate lithiasis: a critical review and future outlook. In: Borghi L., Meschi Т., Briganti A., Schianchi T., Novarini A. eds. Kidney Stones (Proceedings of the 8th European Symposium on Urolithiasis). Editoriale Bios, Parma, Italy; 1999: p.51-57.
    • 64. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy, a double-blind controlled study. Am J Med 1976; 61: p.200-206.
    • 65. Ettinger B., Citron J.T., Livermore B., Dolman L.I. Chlortalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988; 139: p.679-684.
    • 66. Ettinger B., Pak С.Y.С., Citron J.T., Thomas C., Adams-Huet B., Van Gessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997; 158: p.2069-2073.
    • 67. Ettinger B., Tang A., Citron J.T., Livermore B., Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315: p.1386-1389.
    • 68. Folk R.L. SEM imaging of bacteria and nanobacteria in carbonate sediments and rocks. J Sediment Petrol 1993:63:p.990.
    • 69. Giannini S., Nobilc M., Sartori L. et al. Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Am J Clin Nutr 1999; 69: p.261-271.
    • 70. Heilberg I.P., Martini L.A., Draibe S.A., Ajzen H., Ramos O.L., Schor N. Sensitivity to calcium intake in calcium stone forming patients. Nephron 1996; 73: p.145-153.
    • 71. Heilberg I.P., Martini L.A., Szejnfeld V.L. et al. Bone disease in calcium stone-forming patients, din Nephrol 1994; 42: p.175-182.
    • 72. Heilberg I.P., Martini L.A., Szejnfeld V.L., Schor N. Effect of thiazide diuretics on bone mass of nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. J Bone Miner Res 1997; 12: S479 (Abstract).
    • 73. Heilberg I.P., Martini L.A., Teixeira S.H. et al. Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 1998; 79: p.430-437.
    • 74. Hess B. Low calcium diet in hypercalciuric calcium nephrolithiasis patients: first do no harm. Scanning Microsc 1996; 10: p.547-554.
    • 75. Hess B., Jost C., Zipperle L., Takkinen R., Jaeger P. High calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13: p.2241-2247.
    • 76. Hojagaard I., Fornander A.M., Nilsson M.A., Tiselius H.G. Crystallization during volume reduction of solution with a composition corresponding to that in the collecting duct: the influens of hydroxyapatite seed crystals and urinary macromolecules. Urol Res 27: 1999:p.417
    • 77. Holmes R.P., Goodman H.O., Hart L.J., Assimos D.J. Relationship of protein intake to urinary oxalate and glycolate excretion. Kidney Int 1.993; 44: p.366-372.
    • 78. Hosking D.H., Erickson S.B., Van Den Berg C.J., Wilson D.H., Smith L.H. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urot 1983; 130: p.1115-1118.
    • 79. Hughes C., Dutton S., Trusell A. High intakes of ascorbic acid and urinary oxalate. J Hum Nutr 1981; 35: p.274-280.
    • 80. Jaeger P., Lippuner K., Casez Jp., Hess B., Ackermann D., Hug C. Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Min Res 1994; 9: p.1525-1532.
    • 81. Kajander E.O., Bjorklund M., Ciftcioglu N. Mineralisation by nanobacteria. Proc SPIE Int Soc Opt Eng 1998: 3441: p.86.
    • 82. Kajander E.O, Ciftcioglu N. Nanobacteria as extremophiles. Proc SPIE Int Soc Opt Eng 2000:3755:106.
    • 83. Kajander E.O, Ciftcioglu N., Aho K. Detection of nanobacteria in viral vaccines. Proceeding of the American Society of Microbiology, 101st General Meeting 20-24 May 2001, Orlando. Abstract Y-3, p 736.
    • 84. Kajander E.O., Kironen I., Akerman K., Pelttari A., Ciftcioglu N. Nanobacterial from blood, the smallest autonomously replicating agent on Earth. Proc SPIE Int Soc Opt Eng 1997:3111:420
    • 85. Kwak С. et al.. Urinary Oxalate level and the Enteric Bacterium Oxalobacter formingenes in Patients with Calcium Oxalate Urolithiasis. European Urology 44, 2003, p. 475-481.
    • 86. Laerum E., Larsen S. Thiazide prophylaxis of Urolithiasis. Acta Med Scand 1984: 215: p.383-389.
    • 87. Leiske J.C., Toback F.G. Renal cell-urinary crystal interaction. Curr Opin Nephrol Hypertens.-2000, 9: p.349.
    • 88. Lemann J.J., Adams N.D., Gray R.W. Urinary calcium excretion in human beings. N Engl J Meet 1979; 301: p.535-541.
    • 89. Lemann J.J., Pleuss J.A., Gray R.W., Hoffmann R.G. Potassium administration increases and potassium deprivation reduces urinary calcium excretion in healthy adults. Kidney Int 1991; 39; p.973-983.
    • 90. Marangella M., Fruttero B., Bruno M., Linari F. Hyperoxaluria in idiopathic calcium stone disease: further evidence of intestinal hyperabsorption of oxalate. Clin Sri 1982; 63: p.381-385.
    • 91. Marangella M., Vitale C., Petrarulo M., Rovera L., Dutto F. Effects of mineral composition of drinking water on risk for stone formation and bone metabolism in idiopathic calcium nephrolithiasis. din Sci 1996; 91: p.313-318.
    • 92. Marshall R.W., Cochran M., Hodgkinson A. Relationships between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal-stone-forming subjects. Clin Sci 1972; 43: p.91-99.
    • 93. Martini L.A., Cuppari L., Cunha M.A., Schor N., Heilberg. Potassium and sodium intake and excretion in calcium stone forming patients. J Renal NuU 1998; 8: p.127-131.
    • 94. Martini L.A., Heilberg I.P., Cuppari L., Medeiros F.A.M., Draibe S.A., Ajzen H., Schor N. Dietary habits of calcium stone formers. Brazilian J Med Biol Res 1993; 26: p.805-812.
    • 95. Martini L.A., Szejnfeld V.L., Colugnati A.B., Cuppari L., Schor N., Heilberg I.P. High sodium chloride intake is associated with low bone density in calcium stone forming patients, din Nephrol 1999: 80: p.60-65.
    • 96. Massey L.K., Roman-Smith H., Sutton R.A. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. J Am Diet Assoc 1993; 93: p.901-906.
    • 97. Massey L.K., Whiting S.J. Dietary salt, urinary calcium and bone loss. J Bone Miner Res 1996; 11: 731-736.
    • 98. Miller-Hjelle MA, Hjelle JT, Ciftcioglu N, Kajander EO (2003) Nanobacteria: method for growth and identification of the recently discovered calciferous microbe. In Olson W (ed) Rapid analytical microbiology: the chemistry and physics of microbial identification. Sue Horwood, Storrington.
    • 99. Muldowney F.P., Freaney R., Moloncy. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22: 292-296.
    • 100. Nishiura J.L., Martini L.A., Andriolo A., Schor N., Heilberg I.P. Effect of calcium intake upon urinary oxalate excretion in calcium stone forming (CSF) patients. In: Borghi L., Meschi Т., Briganti A.,. Schianchi Т., Novarini A. eds Kidney Stones (Proceedings of the 8th European Symposium on Urolithiasis). Editoriale Bios, Parma, Italy, 1999: p.511-512.
    • 101. Pak C.Y.C. Kidney stones. Lancet 1998; 351: p.1797-1801.
    • 102. Pak C.Y.C. Medical prevention of renal stone disease. Nephron 1999; 81 Suppl 1): p.60-65.
    • 103. Pak C.Y.C., Kaplan R., Bone H., Townsend J., Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciuria. N Engl J Med 1975; 292: p.497-500.
    • 104. Pietschmann F., Breslau N.A., Pak С.Y.С. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7: p.1383-1388.
    • 105. Price P.A., Thomas G.R., Pardini A.W., Figueira W.F., Caputo G.M., Williamson M.K. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix -carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 2002:277: p.3926.
    • 106. Ramello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. J nephrol.- 2000.,13:S45.
    • 107. Randall A. The origin and growth of renal calculi. Ann Surg 1937:105: p.1009.
    • 108. Rodgers A.L. Effect of mineral water containing calcium and magnesium on calcium oxalate Urolithiasis risk factors. Urol Int 1997; 58: p.93-99.
    • 109. Sakhaee K., Harvey J.A., Padalino P.K., Whitson P., Pak С.Y.С. The potential role of salt abuse on the risk for kidney stone formation. J Urol 1993; 150: p.310-312.
    • 110. Sakhaee K., Nicar M., Hill K., Pak C.Y.C. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24: p.348-352.
    • 111. Schvartz G.J., Haycock G.B., Edalmann C.M., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58: p.259-63.
    • 112. Seltzer M.A., Low R.K., McDonald M., Shami G.C., Stoller M.L. Dietary manipulation with lemonade to treat hypocitraturic nephrolithiasis. J Urol 1996; 156: p.907-909.
    • 113. Shokeir A.A. Renal Colic: Pathophysiology, Diagnosis and Tratment. Eur Urol 2001; 39: p.241-9.
    • 114. Siener R. and all. Prospective Study on the efficacy of Selective Treatment and Risk Factors for Relapse in Reccurent Calcium Oxalate Stone Patients. European Urology 44, 2003, p. 467-474.
    • 115. Siener R., Albrecht Hesse. The effect of Different Diets on Urine Composition and the Calcium Oxalate Cristallisation in Healthy Subject. European Urology 42, 2002, р. 289-296.
    • 116. Soygur T, Akbay A, Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J. Endourol. 2002 Apr;16(3):р. 149-52.
    • 117. Tiselius H-G., Ackermann O., Alken P., Buck C., Conort P., Gallucci M.// Guidelines on urolithiasis, 1998.
    • 118. Tiselius H.G. Drug treatment: a critical review and future outlook. In: Borghi L., Meschi Т., Briganti A., Schianchi Т., Novarini A. eds. Kidney Stones (Proceedings of the 8th European Symposium on Urolithiasis). Editoriale Bios, Parma, Italy: 1999: p.127-128.
    • 119. Tiselius H.-G. Epidemiology and medical management of stone disease. BJU international 2000, 91, p.758-767.
    • 120. Trinchieri A., Nespoli R., Ostini F., Rovera F., Zanetti G., Pisani E. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 1998; 159: p.654-657.
    • 121. Wabner C.L., Pak С.Y.С. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993; 149: p.1405-1408.
    • 122. Wandzilak Т., D'Andre S., Davis P., Williams H. Effect of high dose of vitamin С on urinary oxalate levels. J Urol 1994; 151: p.834-837.
    • 123. Weisinger J.R. New insights into the pathogenesis of idiopathic hypercalciuria: The role of bone. Kidney Int 1996; 49: p.1507-1518.
    • 124. Zanchetta J.R., Rodrigucz G., Negri A.L., del Valle E., Spivacow R. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron 1996; 73: p.557-560.

    250-258

    Назад Вперед